New shot takes aim at genetic high cholesterol

NCT ID NCT07465263

Recruiting now Disease control Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This Phase 3 trial tests an injection called SYH2053 for people with heterozygous familial hypercholesterolemia (HeFH), a genetic condition causing very high LDL cholesterol. About 135 adults on stable statin therapy will receive either the drug or a placebo. The main goal is to see how much LDL cholesterol drops after about 11 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYH2053 injection
What this could lead to: If successful, this could provide a new treatment option to lower LDL cholesterol in people with HeFH, potentially reducing their risk of heart disease.
What could go wrong: This is a Phase 3 trial, but it is not yet recruiting and only includes 135 participants. The drug may not lower cholesterol enough or could have side effects. Results may not apply to all HeFH patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial hypercholesterolemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.